Samsara BioCapital’s Surrozen SRZN Stock Holding History

Samsara BioCapital’s Portfolio SRZN Stock Details SRZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-241,400	Closed	-$3.11M	–	26
2025 Q3	$3.11M	Hold	241,400	–	–	0.41%	21
2025 Q2	$2.16M	Hold	241,400	–	–	0.44%	21
2025 Q1	$2.81M	Buy	+241,400	New	+$2.81M	0.5%	21
2023 Q2	–	Sell	-20,000	Closed	-$181K	–	53
2023 Q1	$181K	Hold	20,000	–	–	0.04%	51
2022 Q4	$175K	Hold	20,000	–	–	0.04%	51
2022 Q3	$606K	Hold	20,000	–	–	0.14%	47
2022 Q2	$900K	Hold	20,000	–	–	0.24%	45
2022 Q1	$903K	Hold	20,000	–	–	0.23%	47
2021 Q4	$1.93M	Hold	20,000	–	–	0.37%	37
2021 Q3	$2.12M	Buy	+20,000	New	+$2.81M	0.33%	38

Other funds holding SRZN

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Samsara BioCapital's SRZN Position: Q4 2025 in Review

Samsara BioCapital sold out of Surrozen (SRZN) in Q4 2025, closing a stake of 241,400 shares — an estimated $3.11M sold.

Samsara BioCapital first reported a position in SRZN in Q3 2021 and held it in 10 quarters. The position peaked at $3.11M in Q3 2025. 55 funds tracked by Wall St. Rank hold SRZN as of Q4 2025.

Samsara BioCapital reported no remaining Surrozen position as of Q4 2025 after selling out during the quarter.
Samsara BioCapital sold 241,400 Surrozen shares in Q4 2025, an estimated $3.11M.
Samsara BioCapital first reported a position in Surrozen in Q3 2021 and held it in 10 quarters.
Samsara BioCapital's Surrozen position peaked at $3.11M in Q3 2025.
55 funds tracked by Wall St. Rank held Surrozen as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.